Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3 rd-generation EGFR inhibitors and outperforms other investigational 4 th-generation inhibitors ...

Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable ...

New safety, efficacy and pharmacokinetic results presented from dose escalation portion of the studyAnti-tumour activity observed across all dose levels and in various tumour indicationsNEWCASTLE, ...